InflaRx has been granted a patent for a method of treating cutaneous, neutrophilic, inflammatory diseases like hidradenitis suppurativa using a selective C5a receptor inhibitor called avacopan. This inhibitor shows promise in treating HS-related disorders. GlobalData’s report on InflaRx gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights InflaRx - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on InflaRx, NSAID cancer drugs was a key innovation area identified from patents. InflaRx's grant share as of February 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of hidradenitis suppurativa using c5a receptor inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: InflaRx NV

A recently granted patent (Publication Number: US11890349B2) discloses a method for treating hidradenitis suppurativa (HS) or an HS-related disorder by administering a selective C5a receptor inhibitor to a subject in need. The inhibitor specified in the patent is avacopan, which is described by a specific chemical formula. This method aims to target the C5a receptor, specifically C5aR, to address the symptoms and underlying mechanisms of HS.

Hidradenitis suppurativa is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and sinus tracts in areas with apocrine glands. By utilizing a selective C5a receptor inhibitor like avacopan, the patented method seeks to modulate the immune response associated with HS. The inhibition of the C5a receptor, particularly C5aR, is believed to play a crucial role in reducing inflammation and improving the symptoms of HS. This approach represents a novel and potentially effective treatment strategy for individuals suffering from HS and related disorders.

To know more about GlobalData’s detailed insights on InflaRx, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies